Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)

Archives of Gynecology and Obstetrics

Volumn 284, Issue 1, 2011, Pages 215-220

  Hatam, N ^a   Ahmadloo, N ^b   Ahmad Kia Daliri, A ^c   Bastani, P ^d   Askarian, M ^d  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c LUND UNIVERSITY   (Sweden)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant therapy; Breast cancer; Quality of life; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; AMENORRHEA; ANEMIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; INSOMNIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISCOLORATION; NAIL DISEASE; NEUROTOXICITY; PAIN; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; QUALITY OF LIFE; TAXOIDS;

EID: 79958791086     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-010-1609-8     Document Type: Article

References (25)

1. Micheli A, Goeberg JW, Mugno E et al (2003) European health systems and cancer care. Ann Oncol 14:41-60
2. http://www.mazums.ac.ir/files/onlineJournals-2660610=tosi.pdf
3. Brinton L, Lacey J, Devesa SS (2002) Epidemiology of breast cancer. In: Donegan WL, Spratt JS (eds) Cancer of the breast, vol 2, 5th edn. WB Saunders, Philadelphia, pp 111-132
4. Mant D, Vessey MP (1991) Epidemiology of breast cancer. In: Kirby I, Copeland EM (eds) The breast: comprehensive management of benign and malignant diseases, vol 116. WB Saunders, Philadelphia, pp 363-365
5. Hajian S, Mirzai Najm Abadi KH, Keramat A et al (1998) Systematic survey on the effects of limb relaxation and directed intellectual on pain and distress reduction because of the treatment's side effects on women suffering from breast cancer during 1998-2007 in Farsi. Iran's Breast Dis 1(3):32-43
6. Tirgiri B, Aghebati N, Fazwl A et al (1996) Investigating the relationship between the type of adjuvant therapy with the anxiety, depression and fatigue score in breast cancer patients in Farsi. Razi Fac Nurs Obstet Mag 6:52-59
7. Bonneterre J, Bercez C, Bonneterre M-E, Lenne X, Dervaux B (2005) Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study). Ann Oncol 16(6):915-922 (Pubitemid 40903917)
8. Martin M (2006) Docetaxel doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. Womens Health (Lond Engl) 2(4):527-37
9. Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17(8):1205-1212 (Pubitemid 44288210)
10. Fayers PM, Aaronson NK, Bjordal K et al (2001) On behalf of the EORTC quality of life group. EORTC QLQ-C30 scoring manual (3rd edn), EORTC, Brussels
11. Montazeri A, Harirchi I, Vahdani M (1999) The European organization for research and treatment of cancer quality of life questionnaire (EORTC QLQ-C30): translation and validation study of the Iranian version. Support Care Cancer 7:400-406 (Pubitemid 29489193)
12. Haji Mohamadi M, Ebrahimi M, Jarvandi S et al (2000) The EORTC breast cancer specific quality of life questionnaire (EORTC-BR23): translation and validation study of the Iranian version. Qual Life Res 9(2):177-184
13. Shaban M, Monjamed Z, Mehran A, Hassan Poor Dehkordi A (1383) The relationship between cancer's characteristics and patients' quality of life who treating with chemotherapy in Farsi. Haiat 22:79-84
14. Rom J, von Minckwitz G, Eiermann W, Sievert M, Schlehe B et al (2008) Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Ann Oncol 19:1698-1705
15. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313 (Pubitemid 40740554)
16. Boer K, Lang I, Juhos É, Pinter T et al (2003) Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC) - a Hungarian experience in the BCIRG 001 trial. Pathol Oncol Res 9(3):229-238
17. Martin M, Liuch A, Segul MA et al (2006) Toxicity and health related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC). Ann Oncol 17(8):1205-1212
18. Brain GC, Bachelot T, Serin D, Kirscher S, for the RAPP-01 Trial Investigators et al (2005) Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA 293:2367-2371 (Pubitemid 40676759)
19. http://www.pcpoh.bham.ac.uk/publichealth/horizon/outputs/documents/2004/ docetaxel.pdf
20. Martin M, Pienkowsk T, Mackey J, Pawlicki M et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Eng J Med 352(22):2302-2313, 2346-2348
21. http://www.Cancerhelp.Org.uk/help/default.Asp?Page=4003e=4003
22. http://www.Cancerhelp.Org.uk/help/default.Asp?Page=4025
23. http://www.Cancerhelp.Org.uk/help/default.Asp?Page=4007
24. http://www.Cancerhelp.Org.uk/help/default.Asp?Page=4004
25. Martin M, Vogal C, Crown J, Mackey J (2005) Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer. JAMA 294(17):2166